AUPH
Aurinia Pharmaceuticals Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +20.0% ·
share flow +26.8% ·
net new positions +16.7%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 27.85K | $451,566 | n/a | −1 |
| Q2 2026 | 100 | +2 | 47.31M | $802.51M | +6 | −5 |
| Q1 2026 | 102 | +4 | 44.87M | $664.75M | +6 | −2 |
| Q4 2025 | 99 | 0 | 44.16M | $700.36M | n/a | n/a |
| Q3 2025 | 19 | 0 | 27.17M | $300.26M | n/a | n/a |
| Q2 2025 | 16 | +1 | 17.49M | $148.13M | +1 | n/a |
| Q1 2025 | 12 | 0 | 8.38M | $67.38M | +1 | −1 |
| Q4 2024 | 12 | +2 | 8.32M | $74.71M | +3 | −1 |
| Q3 2024 | 9 | 0 | 3.64M | $26.69M | n/a | n/a |
| Q2 2024 | 9 | n/a | 3.40M | $19.43M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 2.92M | n/a | $26.20M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 1.76M | -0.1% | $15.84M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 3 | Arrowstreet Capital ✦ | 1.08M | New | $9.66M | 0.0% | New | 1 | SEC ↗ |
| 4 | Point72 Asset Management ✦ | 849.62K | New | $7.63M | 0.0% | New | 1 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 700.90K | +44.0% | $6.29M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 463.16K | -18.5% | $4.16M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 7 | Citadel Advisors ✦ | 168.50K | -69.2% | $1.51M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 133.33K | +41.9% | $1.20M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 9 | Millennium Management ✦ | 87.42K | +49.9% | $785,041 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Wellington Management ✦ | 60.75K | New | $545,544 | 0.0% | New | 1 | SEC ↗ ×4 |
| 11 | T. Rowe Price ✦ | 52.10K | +19.1% | $468,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Gotham Asset Management ✦ | 45.00K | +8.8% | $404,064 | 0.0% | ▲ Add | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $9.66M | 0.0% |
| Point72 Asset Management | $7.63M | 0.0% |
| Wellington Management | $545,544 | 0.0% |
Exited
| Norges Bank | $260,450 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 256 holders, 73.58M shares, $1.06B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.94K sh · $190,427
Officer · 20.98K sh · $355,946
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
3.7% of class · View original SEC filing ↗
10.0% of class · View original SEC filing ↗